European Journal of Cancer and Clinical Oncology最新文献_第10页

Dysplasia and the natural history of cervical cancer: Early results of the Toronto cohort study 不典型增生和宫颈癌的自然史:多伦多队列研究的早期结果

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90022-6

Steven A. Narod , D.W. Thompson , M. Jain , Claus Wall , Lois M. Green , Anthony B. Miller

引用次数: 19

MDR1 gene expression and prognostic factors in primary breast carcinomas MDR1基因在原发性乳腺癌中的表达及预后影响因素

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90008-2

Josef Wallner , Dieter Depisch , Martina Hopfner , Karin Haider , Jürgen Spona , Heinz Ludwig , Robert Pirker

引用次数: 51

Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma PVB与BEP交替周期治疗晚期精原细胞瘤的疗效观察

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90013-4

Jourik A. Gietema , Pax H.B. Willemse , Nanno H. Mulder , Jan Oldhoff , Elisabeth G.E. de Vries , Dirk Th. Sleijfer

{"title":"Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma","authors":"Jourik A. Gietema , Pax H.B. Willemse , Nanno H. Mulder , Jan Oldhoff , Elisabeth G.E. de Vries , Dirk Th. Sleijfer","doi":"10.1016/0277-5379(91)90013-4","DOIUrl":"10.1016/0277-5379(91)90013-4","url":null,"abstract":"<div><p>33 patients (median age 39 years) with advanced seminoma were treated with 4 courses of alternating cisplatin-containing chemotherapy PVB/BEP (cisplatin, vinblastine and bleomycin; bleomycin, etoposide and cisplatin). Patients were classified as stage IIC (<em>n</em> = 7), IID (<em>n</em> = 9), III (<em>n</em> = 13) and IV (<em>n</em> = 4). 8 had had prior radiotherapy; 9 had an elevated beta human chorionic gonadotropin (βHCG). 30 patients were evaluable for response and 33 for toxicity. During chemotherapy 3 patients died, 1 due to malignant disease, another due to a cardiac arrest, and 1 patient of a bleomycin pneumonitis. 13 (43%) had a complete remission and 17 (57%) had a clinical partial remission (residual radiographic mass). At a median follow-up of 28 months (range 16–88), 3 patients relapsed, 6–8 months after entry. After completion of therapy there were 2 deaths, 1 due to bleomycin pneumonitis and 1 neither tumour nor treatment related. 26 of 33 (79%) patients achieved a continuously disease-free status. Leucocytopenia and thrombocytopenia of WHO grade <span><math><mtext>3</mtext><mtext>4</mtext></math></span> occurred in, respectively, <span><math><mtext>32</mtext><mtext>33</mtext></math></span> (97%) and <span><math><mtext>20</mtext><mtext>33</mtext></math></span> (61%) of the patients. This study shows that alternating PVB/BEP in this group yields comparable response rates with non-alternating schedules but at the expense of considerable toxicity.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90013-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12884577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Emerging clinical uses for GM-CSF GM-CSF的新兴临床应用

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90039-G

J. Howard Scarffe

引用次数: 36

Testicular dysfunction in Hodgkin's disease before and after treatment 霍奇金病治疗前后睾丸功能障碍

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90017-8

S. Viviani , G. Ragni , A. Santoro , L. Perotti , E. Caccamo , E. Negretti , P. Valagussa , G. Bonadonna

{"title":"Testicular dysfunction in Hodgkin's disease before and after treatment","authors":"S. Viviani , G. Ragni , A. Santoro , L. Perotti , E. Caccamo , E. Negretti , P. Valagussa , G. Bonadonna","doi":"10.1016/0277-5379(91)90017-8","DOIUrl":"10.1016/0277-5379(91)90017-8","url":null,"abstract":"<div><p>Over a 7-year period, semen analysis was performed in 92 male patients with Hodgkin's disease prior to therapy. In 67% of patients semen revealed a decreased chance for fertility (i.e. oligozoospermia, asthenozoospermia and/or teratozoospermia). The mean basal levels of follicle-stimulating hormone (FSH), luteinising hormone, testosterone and prolactin were in the normal range. In 77 patients in complete remission after alternating MOPP/ABVD (mechlorethamine, vincristine, procarbazine, prednisone; doxorubicin, bleomycin, vinblastine, dacarbazine), testicular function was assessed. 87% of patients were azoospermic, 9% had semen abnormalities and only 4% were normospermic. Recovery of spermatogenesis was documented in only 17 of 42 (40%) reassessed patients after a median time of 27 months and was generally not affected by pretreatment sperm quality. After chemotherapy, the mean value of FSH [20.45 (S.E. 1.7) mUI/ml] was significantly superior compared with that of the mean pretreatment values. No difference was documented in the mean testosterone and prolactin values tested before and after treatment. Our findings indicate that, of patients with Hodgkin's disease, about half are affected by hypogonadism before starting chemotherapy. By utilising alternating MOPP/ABVD, persistent testicular dysfunction was documented in half of the patients.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90017-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12996654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 145

Community lifestyle characteristics and lymphoid malignancies in young people in the UK 英国年轻人的社区生活方式特征和淋巴细胞恶性肿瘤

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90037-E

Freda E. Alexander , T. James Ricketts , Patricia A. McKinney , Raymond A. Cartwright

{"title":"Community lifestyle characteristics and lymphoid malignancies in young people in the UK","authors":"Freda E. Alexander , T. James Ricketts , Patricia A. McKinney , Raymond A. Cartwright","doi":"10.1016/0277-5379(91)90037-E","DOIUrl":"10.1016/0277-5379(91)90037-E","url":null,"abstract":"<div><p>Data from a specialist registry of haematopoietic malignancies in England and Wales (1984–1988) have been analysed to investigate variations of incidence by age and diagnostic subtype of lymphoid malignancies in young people (aged 0–24 years). Attention has been focussed on the role of community lifestyle indicators for small areas, derived from routine sources, in an ecological analysis. The predominant conditions were acute lymphoblastic leukaemia (ALL)—42.4%, and Hodgkin's disease (HD)—37.5%. Lowest overall incidence at approximately 8 years of age corresponded to the termination of the childhood peak for ALL. Opposite trends of incidence rates with distance from urban centres (urban distance) were observed for the two age groups: odds ratios (OR) for areas > 20 km from towns and cities were 1.46 (95% confidence interval 1.01–2.12) for ages 0–7 and 0.75 (95% confidence interval 0.56-0.99) for ages 8–24. For the younger group this was entirely attributable to ALL. HD, which was dominant in the older group, had highest incidence in connurbations but the gradient of risk for older onset ALL followed the overall pattern for this age group. A positive relationship with socioeconomic status was evident for both age groups but this was considerably stronger for the older cases (OR = 1.16, 95% confidence interval 1.01-1.33) than for the younger for whom it was not independent of urban distance. These results display an association between expression of lymphoid malignancies in young people and urban distance which is not attributable to socioeconomic status; for urban distances the distribution is shifted towards ALL and towards younger age at onset.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90037-E","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12996587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Paternity in patients with testicular germ cell cancer: Pretreatment and post-treatment findings 睾丸生殖细胞癌患者的父系关系:治疗前和治疗后的结果

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90016-7

Peter Vejby Hansen , Karin Glavind , Jytte Panduro , Mogens Pedersen

{"title":"Paternity in patients with testicular germ cell cancer: Pretreatment and post-treatment findings","authors":"Peter Vejby Hansen , Karin Glavind , Jytte Panduro , Mogens Pedersen","doi":"10.1016/0277-5379(91)90016-7","DOIUrl":"10.1016/0277-5379(91)90016-7","url":null,"abstract":"<div><p>Paternity before and after treatment was investigated in 177 patients with unilateral germ cell tumours of the testis. Before the cancer was diagnosed, 51% had fathered at least 1 child, 9% had a history of infertility and 40% had not wanted to have children. It was estimated that 72% of the patients would have fathered at least 1 child at the age of 40 years. After treatment 41 patients had wished to have children. Infertility was still a problem 5 years after the end of treatment in 53% of these men. No significant differences was observed between patients treated with orchiectomy alone and patients treated with cisplatin-based chemotherapy or subdiaphragmatic irradiation. In 8 patients, infertility was present in spite of an evident recovery of spermatogenesis. Congenital malformations were recorded in 3.8% of the live-born children conceived before the orchiectomy. This incidence did not exceed the Danish national rate, the relative risk being 2.5 (95% confidence limits, 0.9-5.5). No malformations were observed in the 22 children conceived after ending treatment.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90016-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12996653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 51

Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro 复发/难治性卵巢癌所致恶性腹水的治疗:体内和体外使用干扰素-α或干扰素-α联合化疗

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90024-8

W.R. Bezwoda, T. Golombick, R. Dansey, J. Keeping

{"title":"Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro","authors":"W.R. Bezwoda, T. Golombick, R. Dansey, J. Keeping","doi":"10.1016/0277-5379(91)90024-8","DOIUrl":"10.1016/0277-5379(91)90024-8","url":null,"abstract":"<div><p>Intraperitoneal treatment with interferon (IFN) for malignant ascites due to advanced ovarian carcinoma refractory to chemotherapy gave an objective response rate of 36% (<span><math><mtext>7</mtext><mtext>19</mtext></math></span> patients treated). <em>In vitro</em> studies demonstrated that cytotoxicity of peripheral blood monocytes/macrophages was stimulated by IFN. However, peritoneal exudate cells obtained after intraperitoneal treatment with interferon were not stimulated to kill autologous tumour cells. Clinical response was therefore most probably due to a direct inhibitory effect of IFN on growth of malignant cells rather than due to an immune modulatory effect. Using a newly established ovarian cancer cell line (UWOV1), synergy between the growth inhibitory/antitumour effects of IFN and cisplatin was demonstrated at clinically achievable concentrations of each agent. IFN plus cisplatin proved to be more effective than intraperitoneal cisplatin alone in control of peritoneal carcinomatosis. The response rate was <span><math><mtext>5</mtext><mtext>7</mtext></math></span> (77%) for combined modality therapy vs. <span><math><mtext>2</mtext><mtext>9</mtext></math></span> (22%) for intraperitoneal chemotherapy alone. Both <em>in vitro</em> and <em>in vivo</em> studies suggest a role for interperitoneal therapy for control of refractory ascites in ovarian cancer.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90024-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12996659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Activation of prodrugs by targeted enzymes 靶向酶对前药的激活作用

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90003-V

Karl Erik Hellström, Peter D. Senter

引用次数: 11

Studies of the differentiation properties of camptothecin in the human leukaemic cells K562 喜树碱在人白血病细胞K562中分化特性的研究

European Journal of Cancer and Clinical Oncology Pub Date : 1991-11-01 DOI: 10.1016/0277-5379(91)90021-5

Paul M.J. McSheehy, Marco Gervasoni, Vito Lampasona, Eugenio Erba, Maurizio D'Incalci

引用次数: 14